BioSpace News Archive

Covestro, a leading polymer company, is proud to announce its collaboration with PharmaJet, a leading biotech company in needle-free injection technology.

Two Chemical Series Identified to Facilitate Lead Optimisation Activities.

The industry analysis report is considered a valuable source of information about the global Blood and Organ Bank industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The report further provides details about each segments and regions covered in the global Laser Capture Microdissection market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry

Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, announced that it has been notified of the commencement of royalty payments relating to commercial sales of Vaxzevria®.

Travere Therapeutics, Inc. announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria, at the Society for Inherited Metabolic Disorders 43rd Annual Meeting, and the 2022 Genetic Metabolic Dieticians International Conference.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that a late breaking abstract has been accepted at the upcoming American Diabetes Association 82nd Scientific Sessions.

EPS is a Belgian pharmaceutical services and products company, distributor and partner of choice for several pharmaceutical brands on the Benelux market including prescription drugs, medical devices, OTC pharmaceuticals and consumer health products.

Everest Medicines announced that it has entered into a memorandum of understanding for a partnership with China Resources Pharmaceutical Group Limited with the intent to establish an independent company focused on the discovery, development and commercialization of messenger RNA vaccines.

Selecta Biosciences, Inc., a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, announced that it has agreed to sell 27,428,572 shares of its common stock and accompanying warrants to purchase up to 20,571,429 shares of common stock at a combined offering price of $1.41 per share and accompanying warrant.